Castration-resistant
prostate cancer that has become resistant to
docetaxel (DTX) represents one of the greatest clinical challenges in the management of this
malignancy. There is an urgent need to develop novel therapeutic agents to overcome chemoresistance and improve the overall survival of patients. We have designed a novel microtubule destabilizer
(2-(4-hydroxy-1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone (QW-296) and combined it with a newly synthesized hedgehog (Hh) signaling pathway inhibitor 2-chloro-N 1-[4-chloro-3-(2-pyridinyl)phenyl]-N 4,N 4- bis(2-pyridinylmethyl)-1,4-benzenedicarboxamide (
MDB5) to treat
taxane-resistant (TXR)
prostate cancer. The combination of
QW-296 and
MDB5 exhibited stronger anticancer activity toward DU145-TXR and PC3-TXR cells and suppressed
tumor colony formation when compared with single-
drug treatment. Because these drugs are hydrophobic, we synthesized the
mPEG-p(TMC-MBC) [methoxy-poly(
ethylene glycol)-block-
poly(trimethylene carbonate-co-2-methyl-2-benzoxycarbonyl-
propylene carbonate)] copolymer, which could self-assemble into
micelles with loading capacities of 8.13% ± 0.75% and 9.12% ± 0.69% for
QW-296 and
MDB5, respectively. Further, these
micelles provided controlled the respective drug release of 58% and 42% release of
QW-296 and
MDB5 within 24 hours when dialyzed against PBS (pH 7.4). We established an orthotopic prostate
tumor in nude mice using stably
luciferase expressing PC3-TXR cells. There was maximum
tumor growth inhibition in the group treated with the combination
therapy of
QW-296 and
MDB5 in
micelles compared with their monotherapies or combination
therapy formulated in cosolvent. The overall findings suggest that combination
therapy with
QW-296 and
MDB5 has great clinical potential to treat TXR
prostate cancer, and copolymer
mPEG-p(TMC-MBC) could serve as an effective delivery vehicle to boost therapeutic efficacy in vivo.